JP7535569B2 - オピオイドヘキサジエノエート及び選択的に置換されたヘキサジエノエートによってオピオイド受容体の結合を改善する組成物並びに方法 - Google Patents

オピオイドヘキサジエノエート及び選択的に置換されたヘキサジエノエートによってオピオイド受容体の結合を改善する組成物並びに方法 Download PDF

Info

Publication number
JP7535569B2
JP7535569B2 JP2022509137A JP2022509137A JP7535569B2 JP 7535569 B2 JP7535569 B2 JP 7535569B2 JP 2022509137 A JP2022509137 A JP 2022509137A JP 2022509137 A JP2022509137 A JP 2022509137A JP 7535569 B2 JP7535569 B2 JP 7535569B2
Authority
JP
Japan
Prior art keywords
opioid
naloxone
nalbuphine
compound
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022509137A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021029914A5 (https=
JP2022544564A (ja
JP2022544564A5 (https=
Inventor
ニコノフ，ゲオルギー
イサクリアン，リボン
ボロンコフ，マイケル・ブイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kappa Pharma LLC
Original Assignee
Kappa Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/540,058 external-priority patent/US11186585B2/en
Application filed by Kappa Pharma LLC filed Critical Kappa Pharma LLC
Publication of JP2022544564A publication Critical patent/JP2022544564A/ja
Publication of JPWO2021029914A5 publication Critical patent/JPWO2021029914A5/ja
Publication of JP2022544564A5 publication Critical patent/JP2022544564A5/ja
Application granted granted Critical
Publication of JP7535569B2 publication Critical patent/JP7535569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022509137A 2019-08-11 2020-03-07 オピオイドヘキサジエノエート及び選択的に置換されたヘキサジエノエートによってオピオイド受容体の結合を改善する組成物並びに方法 Active JP7535569B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962885311P 2019-08-11 2019-08-11
US62/885,311 2019-08-11
US16/540,058 US11186585B2 (en) 2018-08-17 2019-08-14 Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates
US16/540,058 2019-08-14
PCT/US2020/021599 WO2021029914A1 (en) 2019-08-11 2020-03-07 Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates

Publications (4)

Publication Number Publication Date
JP2022544564A JP2022544564A (ja) 2022-10-19
JPWO2021029914A5 JPWO2021029914A5 (https=) 2023-03-15
JP2022544564A5 JP2022544564A5 (https=) 2023-03-15
JP7535569B2 true JP7535569B2 (ja) 2024-08-16

Family

ID=74571142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022509137A Active JP7535569B2 (ja) 2019-08-11 2020-03-07 オピオイドヘキサジエノエート及び選択的に置換されたヘキサジエノエートによってオピオイド受容体の結合を改善する組成物並びに方法

Country Status (6)

Country Link
EP (1) EP4010078A4 (https=)
JP (1) JP7535569B2 (https=)
CN (1) CN114828961B (https=)
CA (1) CA3149152A1 (https=)
MX (1) MX2022001520A (https=)
WO (1) WO2021029914A1 (https=)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500256A (ja) 2009-07-21 2013-01-07 ネクター セラピューティックス オリゴマー−オピオイドアゴニスト抱合体
JP2014501268A (ja) 2010-12-28 2014-01-20 ユーロ−セルティーク エス．エイ． パーキンソン病の治療におけるオピオイド作動薬とオピオイド拮抗薬との組合せ
JP2014508148A (ja) 2011-02-09 2014-04-03 キューアールエックスファーマ リミテッド ハイブリッドオピオイド化合物および組成物
US20170152266A1 (en) 2015-04-27 2017-06-01 John K. Thottathil Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS Based Prodrugs of Oxycodone and Uses thereof
WO2017095734A1 (en) 2015-12-01 2017-06-08 Thottathil John K Novel alpha-hydroxy carboxylic acid and derivatives and other gras- based prodrugs of oxymorphone and uses thereof
US20170196851A1 (en) 2015-04-27 2017-07-13 John K. Thottathil Novel Alpha-Hydroxy Carboxylic Acid And Derivatives And Other Gras- Based Prodrugs Of Opioids And Uses Thereof
WO2018191472A1 (en) 2017-04-14 2018-10-18 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
EP0615756B1 (en) * 1993-03-15 2001-06-27 National Science Council Nalbuphine esters and long-acting pharmaceutical compositions containing them
CN1050130C (zh) 1997-07-04 2000-03-08 卢正堂 纳洛酮酸脂和纳屈酮酸脂及系列物和制备方法
ES2188481T3 (es) 2000-04-27 2003-07-01 Oliver Yoa-Pu Hu Derivados de polinalbufina.
TWI226239B (en) 2000-05-15 2005-01-11 You-Pu Hu Novel oral pharmaceutical composition containing nalbuphine ester prodrug
CA2771263A1 (en) 2000-07-27 2002-02-07 Rutgers, The State University Therapeutic polyesters and polyamides
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
EP1928881A2 (en) 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
US20090186832A1 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
EP2413937A1 (en) 2009-04-02 2012-02-08 Shire LLC Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
AU2010272233A1 (en) 2009-07-17 2012-02-09 Shire Llc Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
EP2552924B1 (en) * 2010-04-02 2015-09-16 Zynerba Pharmaceuticals, Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
US9974858B2 (en) * 2015-08-29 2018-05-22 Medrx Co., Ltd Percutaneous absorption composition
US11186585B2 (en) * 2018-08-17 2021-11-30 Kappa-Pharma LLC Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500256A (ja) 2009-07-21 2013-01-07 ネクター セラピューティックス オリゴマー−オピオイドアゴニスト抱合体
JP2015180698A (ja) 2009-07-21 2015-10-15 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−オピオイドアゴニスト抱合体
JP2014501268A (ja) 2010-12-28 2014-01-20 ユーロ−セルティーク エス．エイ． パーキンソン病の治療におけるオピオイド作動薬とオピオイド拮抗薬との組合せ
JP2014508148A (ja) 2011-02-09 2014-04-03 キューアールエックスファーマ リミテッド ハイブリッドオピオイド化合物および組成物
US20170152266A1 (en) 2015-04-27 2017-06-01 John K. Thottathil Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS Based Prodrugs of Oxycodone and Uses thereof
US20170196851A1 (en) 2015-04-27 2017-07-13 John K. Thottathil Novel Alpha-Hydroxy Carboxylic Acid And Derivatives And Other Gras- Based Prodrugs Of Opioids And Uses Thereof
WO2017095734A1 (en) 2015-12-01 2017-06-08 Thottathil John K Novel alpha-hydroxy carboxylic acid and derivatives and other gras- based prodrugs of oxymorphone and uses thereof
WO2018191472A1 (en) 2017-04-14 2018-10-18 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEI, C. J. et al.，"Synthesis and antitumor activities of sinomenine derivatives on rings A and C"，Journal of Asian Natural Products Research，2017年，Vol. 20, No. 3，pp. 277-291，DOI: 10.1080/10286020.2017.1386659

Also Published As

Publication number Publication date
MX2022001520A (es) 2022-07-21
CA3149152A1 (en) 2021-02-18
JP2022544564A (ja) 2022-10-19
EP4010078A4 (en) 2023-08-09
WO2021029914A1 (en) 2021-02-18
EP4010078A1 (en) 2022-06-15
CN114828961A (zh) 2022-07-29
CN114828961B (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
US11851439B2 (en) Compositions and methods of use for opioid hexadienoates and optionally substituted hexadienoates
AU2002305816B2 (en) Sustained-release analgesic compounds
CA2827662C (en) Active agent prodrugs with heterocyclic linkers
CN102480959B (zh) 氢可酮的苯甲酸缀合物、苯甲酸衍生物缀合物和杂芳基羧酸缀合物及其前药、制备方法和用途
KR101589846B1 (ko) 히드로모르폰의 벤조산, 벤조산 유도체 및 헤테로아릴 카르복실산 컨쥬게이트, 전구약물, 이의 제조 방법 및 용도
AU2002305816A1 (en) Sustained-release analgesic compounds
US20040204434A1 (en) Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
EP3355885B1 (en) Polysubunit opioid prodrugs resistant to overdose and abuse
WO2012122420A2 (en) Opioid prodrugs with heterocyclic linkers
JP2010511717A (ja) プロドラッグおよびその作成ならびに使用方法
WO2012122412A2 (en) Compositions for reducing risk of adverse events caused by drug-drug interactions
HUP0500024A2 (hu) 6-Aminomorfinán-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
JP7535569B2 (ja) オピオイドヘキサジエノエート及び選択的に置換されたヘキサジエノエートによってオピオイド受容体の結合を改善する組成物並びに方法
TWI356826B (https=)
WO2025216797A1 (en) Dosing of polysubunit opioid prodrugs resistant to overdose and abuse
HK1193976B (en) Active agent prodrugs with heterocyclic linkers
HK1193976A (en) Active agent prodrugs with heterocyclic linkers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240805

R150 Certificate of patent or registration of utility model

Ref document number: 7535569

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150